Business Wire

Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration | Business Wire

Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration ...
Nasdaq

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing -- ARLINGTON, ...
IndustryWeek

Silvon Adds KPI Measurements To Performance-Management Application

Compiled ByDave Schafer Silvon Software Inc. has included more than 65 additional Key Performance Indicators (KPIs) into its newly released Stratum Version 2.0 suite of business performance-management ...
WGN-TV

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, ...
Business Wire

Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease

Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, LE, designed for ocular applications, resulting in recently approved INVELTYS TM for the treatment of inflammation and pain ...